Abstract:Abstract Serine and glycine give rise to important building blocks in proliferating cells. Both amino acids are either synthesized de novo or taken up from the extracellular space. In lung cancer, serine synthesis gene expression is variable, yet, expression of the initial enzyme, phosphoglycerate dehydrogenase (PHGDH), was found to be associated with poor prognosis. While the contribution of de novo synthesis to serine pools has been shown to be enhanced by serine starvation, the impact of glucose deprivation, a commonly found condition in solid cancers is poorly understood. Here, we utilized a stable isotopic tracing approach to assess serine and glycine de novo synthesis and uptake in different lung cancer cell lines and normal bronchial epithelial cells in variable serine, glycine, and glucose conditions. Under low glucose supplementation (0.2 mM, 3–5% of normal plasma levels), serine de novo synthesis was maintained or even activated. As previously reported, also gluconeogenesis supplied carbons from glutamine to serine and glycine under these conditions. Unexpectedly, low glucose treatment consistently enhanced serine to glycine conversion, along with an up-regulation of the mitochondrial one-carbon metabolism enzymes, serine hydroxymethyltransferase (SHMT2) and methylenetetrahydrofolate dehydrogenase (MTHFD2). The relative contribution of de novo synthesis greatly increased in low serine/glycine conditions. In bronchial epithelial cells, adaptations occurred in a similar fashion as in cancer cells, but serine synthesis and serine to glycine conversion, as assessed by label enrichments and gene expression levels, were generally lower than in (PHGDH positive) cancer cells. In summary, we found a variable contribution of glucose or non-glucose carbon sources to serine and glycine and a high adaptability of the downstream one-carbon metabolism pathway to variable glucose supply.

Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer

The ins and outs of serine and glycine metabolism in cancer

Regulation of cancer metabolism by O-GlcNAcylation

Serine and one-carbon metabolism in cancer

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation

Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides

Suppression of nuclear GSK3 signaling promotes serine/one-carbon metabolism and confers metabolic vulnerability in lung cancer cells

Sensitisation of cancer cells to radiotherapy by serine and glycine starvation

Serine synthesis and catabolism in starved lung cancer and primary bronchial epithelial cells

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy

Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies

The Molecular Determinants of De Novo Nucleotide Biosynthesis in Cancer Cells

Abstract SY41-03: Cancer specific amino acid metabolism

Lysine catabolism reprograms tumour immunity through histone crotonylation

Exploiting De Novo Serine Synthesis as a Metabolic Vulnerability to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma

De novo synthesis of serine and glycine fuels purine nucleotide biosynthesis in human lung cancer tissues

NRF2 Regulates Serine Biosynthesis in Non-Small Cell Lung Cancer

NRF2 SUMOylation Promotes De Novo Serine Synthesis and Maintains HCC Tumorigenesis.

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer

Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1